Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
8 hedge funds and large institutions have $780K invested in Rosetta Genomics Ltd. in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
20% less funds holding
Funds holding: 10 → 8 (-2)
30% less capital invested
Capital invested by funds: $1.11M → $780K (-$329K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$44.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$23.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$33.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$26.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$705 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
1
Highlander Capital Management
Short Hills,
New Jersey
| $402K | -$33.9K | -2,784 | -6% |
|
|
2
Morgan Stanley
New York
| $281K | +$44.6K | +3,666 | +15% |
|
3
California Public Employees Retirement System
Sacramento,
California
| $42K | – | – | – |
|
|
VKH
4
Virtu KCG Holdings
New York
| $20K | -$705 | -58 | -3% |
|
|
TSS
5
Two Sigma Securities
New York
| $19K | +$23.4K | +1,928 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $13K | -$26.8K | -2,206 | -62% |
|
7
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
8
Citigroup
New York
| $1K | – | – | – |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$25K | -1,783 | Closed |
|
ROSG Hedge Fund Activity: Q3 2016 in Review
8 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q3 2016, worth a combined $780K — down 30% from $1.11M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ROSG and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $44.6K. The largest seller was Highlander Capital Management, cutting an estimated $33.9K.
- 8 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q3 2016, down from 10 in Q2 2016.
- Funds reported $780K of Rosetta Genomics Ltd. stock for Q3 2016, down 30% quarter-over-quarter.
- 1 fund opened new Rosetta Genomics Ltd. positions in Q3 2016 and 2 closed out, a net change of -1 holder.
- The largest Rosetta Genomics Ltd. buyer in Q3 2016 was Morgan Stanley, an estimated $44.6K added.
- The largest Rosetta Genomics Ltd. seller in Q3 2016 was Highlander Capital Management, an estimated $33.9K sold.
Based on aggregated 13F filings for Q3 2016.